Merck: Business Analysis Merck is a flourishing research-driven pharmaceutical company‚ which discovers‚ develops‚ manufacturers‚ and promotes an extensive variety of human and animal health products. Although Merck is one of the biggest pharmaceutical companies of the world‚ they still come across problems today while striving to sustain a lead against its competition. Merck has achieved success with its lengthy history of breakthrough drugs and the development of three significant pharmaceutical
Premium Human resource management Pharmaceutical industry Human resources
EXECUTIVE SUMMARY Statement of the Problem Merck & Co.‚ Inc.‚ a leading pharmaceutical company‚ faces the threat of the patents of its most popular drugs expiring in 2002. The only way to counter the loss of sales from these drugs going off patent is to develop new drugs in order to refresh the company’s portfolio. LAB Pharmaceuticals‚ a small pharmaceutical company who specializes in the treatment of neurological disorders‚ has approached Merck with the opportunity to license Davanrik‚ a new
Premium Patent Pharmacology Pharmaceutical drug
Merck SWOT Analysis MGT/521 July 25‚ 2012 Merck SWOT Analysis Company Overview Merck is the 2nd largest pharmaceutical company in world offering prescription medications‚ biologics‚ vaccines‚ animal health‚ and consumer care products. It generated 48 billion dollars in revenue in 2011 and has 40‚000 employees. Research and development of proprietary medicines for global marketing is the core of the business. Recent acquisitions and transactions designed to take advantage
Premium Management Strategic management Marketing
As a result of worldwide withdrawal of Vioxx‚ Merck faced a serious public relations crisis in the fall of 2004. Pharmaceutical giant’s officials were forced to defend company’s actions‚ its motivation for those actions‚ and its reputation after several articles‚ negatively reflecting on Merck’s behavior handling the Vioxx case‚ had been published. As an initial response to Vioxx crisis‚ the company released “An Open Letter from Merck” and “For 100 years‚ patients first” in attempt at a positive
Premium Pharmacology Pharmaceutical drug Drug
CEO Ray Gilmartin Merck’s CEO Ray Gilmartin is a significant stakeholder in the company. Since a lot of Mercks’ products patents will be expiring in the next few years Gilmartin put a big emphasis on investing into the companies research and development of new products. Gilmartin wanted this company to really focus on coming out with new products because their bottom line was going to take a hit in the next few years once the patent on their big money products runs out. Gilmartin found it an
Premium Pharmacology Finance Management occupations
MERCK: OPEN FOR INNOVATION? Founded in 1891 as an American subsidiary of his German namesake‚ Merck was once considered the “undisputed king of the pharmaceutical industry with ground‐ breaking drugs”(The Chief Executive 2003). But for the last decade‚ Merck has gone through a period of stagnation; it began to lose exclusivity patents on blockbuster drugs and has witnessed Pfizer’s rise to top place in the industry. It seemed now that internal R&D that was once the company’s main asset would
Premium Pharmaceutical industry
Merck & Co. Executive Summary Case Study Goal The goal of this case study is to examine the current operations of Merck & Co. Inc. and determine areas of potential concern‚ evaluate the effectiveness of the current business model‚ and propose a plan of action to grow Merck & Co. Inc. to be the largest pharmaceutical company in the world. Methods of Analysis This case study will strive to identify areas of concern and opportunity‚ offer solutions‚ and make projections based upon historic data
Premium Financial ratio Financial ratios Strategic management
Merck‚ the FDA‚ and the VIOXX Recall MBA 520-D4C2 Ethics & Leadership in a Global Environment April 22‚ 2012 Merck and Vioxx Recall Did Merck act in social and ethical manner? In 2005‚ Merck was ranked fourth in sales among pharmaceutical companies. Merck had released the drug Vioxx‚ for treating Osteoarthritis in late 1990. Merck as a company has a reputation of being one of the most ethical and
Premium Marketing Brand Management
In the year 2000‚ Merck produced a controversial product called Vioxx. Four years later it gained worldwide attention because of the drug’s potential cardiovascular risks. This was detrimental to the company’s reputation because it was alleged Merck knowingly distributed Vioxx despite its risk. Both Barbara Martinez and Anne W. Mathews of the Wall Street Journal wrote articles into the investigation of Vioxx. Their article suggests Merck knew the dangers of Vioxx at an early stage of its clinical
Premium Clinical trial
Merck & Co.‚ Inc.‚ which is a global health care company that delivers innovative health solutions through its prescription medicines‚ vaccines‚ biologic therapies‚ animal health‚ and consumer care products‚ has a long and rich history of working. There are some main stages of the whole history and background information. In 1851‚ Dr. Emst Christian Friedrich Schering begins developing and selling pharmaceutical products in Berlin. Three years later‚ the company opened its first production facility
Premium Health care Medicine Revenue